From: Clinical relevance of glomerular IgM deposition in patients with lupus nephritis
Characteristic | Value |
---|---|
Number of patients | 217 |
Age (mean ± s.d.) (years) | 32.7 ± 11.9 |
Gender (female/male) | 182/35 |
The time between presentation of lupus nephritis and biopsy (median, range) (months) | 23 (0–214) |
Duration of follow-up (median, range) (months) | 49 (6–240) |
SLEDAI (mean ± s.d.) | 17.5 ± 5.7 |
Number of fever (non-infectious) (%) | 66 (30.4) |
Number of eruption (%) | 120 (55.3) |
Number of photosensitivity (%) | 50 (23) |
Number of oral ulcer (%) | 64 (29.5) |
Number of arthralgia (%) | 118 (54.4) |
Number of neurological disorder (%) | 12 (5.5) |
Number of anemia (%) | 143 (65.9) |
Number of thrombocytopenia (%) | 66 (30.4) |
Number of leukocytopenia (%) | 101 (46.5) |
Number of hematuria (%) | 166 (76.5) |
Number of leukocyturia (non-infection) (%) | 113 (52.1) |
Number of acute renal failure (%) | 40 (18.4) |
Hemoglobin (mean ± s.d.) (g/L) | 101.9 ± 25.8 |
Urine protein (mean ± s.d.) (g/24 h) | 4.3 ± 3.2 |
Serum creatinine (median, IQR) (μmol/L) | 84 (68–129) |
C3 (mean ± s.d.) (g/L) | 0.46 ± 0.23 |
C4 (mean ± s.d.) (g/L) | 0.23 ± 0.17 |
Antinuclear antibody positive (%) | 214 (98.6) |
Anti-dsDNA antibodies positive (%) | 152 (70.0) |
Anti-Smith antibodies positive (%) | 51 (23.5) |
Anti-SSA antibodies positive (%) | 101 (46.5) |
Anti-SSB antibodies positive (%) | 24 (11.1) |
Anti-C1q antibodies positive (%) | 90 (41.5) |